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MinorityReport, software for generalized 
analysis of causal genetic variants
Jeremy A. Horst1*, Wesley Wu1 and Joseph L. DeRisi1,2
Abstract 
Background: The widespread availability of next generation genome sequencing technologies has enabled a wide 
range of variant detection applications, especially in cancer and inborn genetic disorders. For model systems and 
microorganisms, the same technology may be used to discover the causative mutations for any phenotype, including 
those generated in response to chemical perturbation. In the case of pathogenic organisms, these approaches have 
allowed the determination of drug targets by means of resistance selection followed by genome sequencing.
Results: MinorityReport is open source software written in python that facilitates the comparison of any two sets of 
genome alignments for the purpose of rapidly identifying the spectrum of nonsynonymous changes, insertions or 
deletions, and copy number variations in a presumed mutant relative to its parent. Specifically, MinorityReport relates 
mapped sequence reads in SAM format output from any alignment tool for both the mutant and parent genome, 
relative to a reference genome, and produces the set of variants that distinguishes the mutant from the parent, all 
presented in an intuitive, straightforward report format. MinorityReport features tunable parameters for evaluating 
evidence and a scoring system that prioritizes reported variants based on relative proportions of read counts support-
ing the variant in the mutant versus parent data sets. The utility of MinorityReport is demonstrated using previously 
published publicly available data sets to find the determinants of resistance for novel anti-malarial drugs.
Conclusions: MinorityReport is readily available (github: JeremyHorst/MinorityReport) to identify the genetic mecha-
nisms of drug resistance in Plasmodium, genotype-phenotype relationships in human diads, or genomic variations 
between any two related organisms.
Keywords: Bioinformatics, Mutation, Genotype-phenoype, Drug mechanism, Genetic etiology, CNV, Missense
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Sequencing to characterize genotype‑phenotype 
relationships
The advent of robust high throughput genetic sequencing 
methods has made genome sequencing tractable for any 
sample from any organism. Comparison of genomes for 
related organisms (within the same lineage of a species) 
with different physiologic, behavioural, or anatomic phe-
notypes has been increasingly used to characterize the 
genetic determinants of the feature, i.e. genotype-pheno-
type relationships. Differences in the genome sequences 
of two related organisms with a different phenotype 
describe the possible causal genetic variants (see Fig. 1). 
This technique has been used to find the molecular deter-
minants of resistance for novel compounds against the 
causative agent of the most deadly form of malaria, Plas-
modium falciparum [1], including a drug now in clinical 
trials [2], and an inhibitor of the apicoplast—an organelle 
unique to Apicomplexa [3]. The same principles have 
been used to find novel mutant genes underlying human 
craniofacial congenital malformations including cranio-
synostosis [4], auriculocondylar syndrome and thereby 
the universal signal for lower jaw patterning [5], and 
acromelic frontonasal dysostosis [6]. Beyond congenital 
anomalies and drug targets, this experimental system is 
relevant to any genotype-phenotype study.
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How to
To perform this analysis, genomic sequencing reads from 
each organism (e.g. in FASTQ format) are first aligned to 
the reference genome FASTA file, resulting in Sequence 
Alignment/Map (SAM) format files [7]. The observed vari-
ations from the reference genome are then evaluated for 
sufficient supporting evidence by quantity and proportion 
of reads in the mutant, and support for non-variation in 
the parent. The variants that pass these threshold filters 
are then placed in the context of coding sequences, defined 
in gene file format files (GFF3), to determine whether the 
variant changes the gene product, i.e. is nonsynonymous 
(Fig.  2). Variants observed consistently in multiple inde-
pendent pairs of organisms that differ in the same manner 
are likely to be the causal genetic variant that underlies the 
phenotype. In the case of drug resistance selections, the 
underlying assumption for a mutation or copy-number 
variant which leads to resistance is that it will be under 
purifying selection unlike other variants present in the 
population at the time of the initial selection.
This process requires the reference genome and gene 
model, and deep sequencing data for unaffected parents 
and the affected child for humans, or similarly the drug-
sensitive parent strain and the derivative drug-resistant 
mutants for pathogens. The reference genome is required 
as a contextual template to align the sequencing reads 
and thereby identify genetic variants. The gene model is 
needed to identify whether a variant is in a protein-cod-
ing region, and whether the variant changes the resulting 
protein sequence.
While this process is straightforward in concept, many 
bioinformatic analysis computer programs work only 
on one or an arbitrary set of organisms, e.g. human and 
mouse, or do not integrate both mutation and copy-
number variant analysis into a unified pipeline. A few 
robust generalized tools are available to call variants 
between one set of sequencing reads against any refer-
ence genome, and a subset of these call nonsynonymous 
variants. However, these tools require extensive data 
preparation, have software library dependencies that 
complicate installation, are sensitive to the many imper-
fections in gene models for the many poorly character-
ized organisms (i.e. they fail to complete running or give 
any output), and they do not perform comparative analy-
sis between multiple sequencing sets. In practice, many 
researchers cobble together pipelines based on several 
different tools to accomplish this task.
Freedom of alignment
Alignment algorithms continue to evolve at rapid pace, 
and the most recent iterations capture alignments to 
much more dissimilar sequences with inexact matches 
and significant insertions or deletions (indels). e.g. Bow-
Tie2, handle indels of limited size, and further sequence 
differences [8]. Algorithms such as STAR [9] and GSNAP 
[10] handle extensive indels, and highly distinct but still 
recognizably similar read-genome sequence matches. 
These advances are useful to address the genotype-phe-
notype problem. Fortunately, these and other genome 
alignment algorithms have converged on a standard SAM 
format [7] which enable downstream applications, such 
as the one described here, to be independent of the base 
aligner.
Fig. 1 Experimental scheme. MinorityReport deciphers nonsyn-
onymous mutations, including those that enable drug resistance in 
pathogens. A susceptible pathogen strain (green) is cultivated in sub-
LD100 concentrations of a drug until a resistant strain (blue) emerges. 
The genomes are sequenced, aligned to a reference genome, and 








Fig. 2 Software flow chart. MinorityReport relates mapped sequence 
reads in SAM format output from any alignment tool for both the 
mutant and parent genome, relative to a reference genome, to the 
protein coding sequence, and produces the set of nonsynonymous 
variant that distinguish the mutant from the parent
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Copy number variants
Another major type of genetic anomaly that can underlie 
genotype-phenotype relationships is a gene copy num-
ber variant (CNV). When the function of a gene becomes 
particularly adaptive, useless, or harmful, environmental 
pressures can select for the replication or loss of any num-
ber of copies of a gene or set of genes [11]. Because CNVs 
affect gene dosage, they have the potential for physiologic 
impact. Various approaches are used to detect CNVs on 
a large scale, with the primary clinical tool being array 
comparative genomic hybridization [12]. Algorithms 
have been constructed to use indirect evidence to evalu-
ate CNVs, such as inference through analysis of single 
nucleotide polymorphism (SNP) chips [13]. However, as 
with all microarray technologies, next generation genome 
sequencing technologies are replacing the use of array 
CGH and SNP chips due to their portability to any bio-
logical system, and unbiased sequence data generation. 
The normalized abundance of sequencing reads that map 
to each gene is a direct measure of the number of copies 
of the gene. CNVs can be estimated using sparse read cov-
erage data sets as well [11]. However, the enormous num-
ber of reads accessible through contemporary sequencing 
instruments (e.g. the Illumina HiSeq series) makes direct 
assessment through deep coverage straightforward.
Results and discussion
MinorityReport facilitates the comparison of any two sets 
of genome alignments for the purpose of rapidly identify-
ing the spectrum of nonsynonymous or indel changes in 
a presumed mutant relative to its parent. In addition, the 
data model for detecting nonsynonymous variants inte-
grates rapid assessment of CNVs. Tunable parameters for 
both analyses enable reporting of high or low purity non-
synonymous mutations, and large or small range CNV 
detection. This software does not address noncoding vari-
ants such as promoter or enhancer element mutations, 
intergenic variants that may occur in encoded functional 
RNAs, nor chromosomal rearrangements, which may 
be assessed with the same sequencing data. Algorithms 
deployed in this software are described, and utility is 
demonstrated on freely available data sets that carry the 
genetic determinants of resistance for anti-malarial drugs.
Nonsynonymous variant caller algorithm
A simplified flow chart of the nonsynonymous variant 
caller algorithm in MinorityReport is shown in Fig.  2. 
FASTA and GFF3 files for the reference genome are taken 
as input to build the gene model. Indices for genes, exons, 
and splice variants are taken from coding sequence lines 
(those with CDS entered in the phase column). Gene 
descriptions are taken from gene lines. Reverse com-
pliment indices are translated for genes present on the 
negative strand (python list indices are inclusive at the 
beginning but exclusive at the end, so must be shifted 1 
nucleotide towards the 3′ direction). Sequences are found 
from these indices in the reference genome FASTA file, 
and checked for start and stop codons. Next, a hash table 
(python dictionary) is made from the reference genome 
FASTA file to store the sequence evidence: for each 
sequence position in each chromosome a key is created 
for each of the possible 4 nucleotides, and a zero value is 
entered (indels are added later).
Sequence Alignment/Map files of sequencing reads 
aligned to the reference genome for the parent and mutant 
are each taken as input and applied into separate sequence 
evidence hash tables. For each mapped read pair, the mate 
pair read is checked for matched mapping location. The 
CIGAR entry is read for presence of insertions or deletions 
(indels) in the read. The mapped strand is extracted from 
the binary flag entry. Finally, each nucleotide in each paired 
read is added into the sequence evidence hash table. Inser-
tions and deletions are added to the position entry as they 
occur, and counted the same way as nucleotides. An exam-
ple position: “sequence_evidence[‘chr7’] [1423712] = {‘A’:3, 
‘C’:5, ‘G’:51, ‘T’:3, ‘–’:426, ‘AACTAC’:20}” where chr7 is 
the chromosome, 1423712 is the position on chromo-
some 7, and 3 A’s, 5 C’s, 51 G’s, 3 T’s, 426 deletions, and 20 
ACTAC insertions are observed at the position. Insertions 
are denoted in the direction of the positive strand; the first 
nucleotide in the insertion entry is technically not part of 
the insertion, but is counted in the insertion to enable a 
consistent notation system.
Next, the sequence evidence hash tables are scanned 
for nonsynonymous variants that appear in the mutant 
but not the parent. Chromosomes are read in turn. Then 
evidence thresholds are applied to each entry of the 
position in a progression to maximize efficiency: vari-
ant of the reference genome, supra-threshold number of 
mutant reads and fraction of reads at the position sup-
port the variant, supra-threshold number of parent read 
coverage, subthreshold number of parent reads and 
fraction of reads at the position support the variant, the 
variant is in a coding sequence region, and the variant 
changes an amino acid in the translated protein sequence 
(nonsynonymous). Variants passing these criteria are 
reported (Table  1). Each reported variant is assigned a 
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mutationmutant refers to the quantity of sequencing 
reads that contain the variant in the mutant sample, and 
similarly mutationparent refers to the same in the par-
ent sample. nonmutationmutant refers to the quantity of 
reads that contain anything other than the variant in the 
mutant sample. position variables refer to the total num-
ber of reads overlapping the position of the variant in 
each sample, and µ refers to the mean number of reads 
overlapping any position in the genome for each sample.
The rationale for the terms in the priority score calcula-
tion is as follows. The relative abundance of sequencing 
reads that identify a nucleotide or indel (variant) com-
prises the evidence for the variant. Reads that identify 
any other allele at the position, and reads identifying the 
same variant in the parent strain comprise the evidence 
against the variant being novel and causal. Low coverage 
in either the parent or mutant samples would decrease 
confidence in the variant, so high relative coverage of the 
samples increases prioritization.
CNV caller algorithm
As each position in each chromosome is scanned for 
nonsynonymous variants unique to the mutant, the total 
counts in each of parent and mutant for each position 
are applied to a CNV evidence model. After the nonsyn-
onymous variant scan is complete for each chromosome, 
the genome is evaluated for regions with significant dif-
ferences in median read coverage between mutant and 
parent. The probability of the parent or mutant being sig-
nificantly high or low in copy number (gene abundance) 
is estimated by relating the number of reads that map to 
the position to the mean and standard deviation for the 
chromosome, i.e. the z-score. Positions are considered 
significant when a number of reads are mapped in the 
mutant that correspond to being above or below a prob-
ability threshold or number of copies, with respect to the 
parent.
Copy number variants are calculated as the ratio of 
reads that map to each sliding window in the mutant and 
parent data sets, normalized by the total number of reads 
for the parent and mutant. The probability of observing a 
CNV at random for each variant is estimated by placing 
the log2 transform in the context of log2 normalized read 
ratios for all sliding windows assessed across the genome. 
The resulting z-score (z = (x–mean)/standard deviation) 
is transformed to a probability estimate by the Gaussian 
transformation.
The CNV-seq algorithm is widely used to calculate 
CNVs from sequencing data [11]. The CNV-seq algo-
rithm calculates the probability for each observed CNV 
occurring at random using the covariation of the read 
numbers in the parent and mutant data sets, with the 
Geary-Hinkley transformation. As seen in Figs. 3, 4 and 
5, read coverage is not homogenous. Areas with devia-
tions in coverage due to external processing factors, 
such as the non-uniform distribution of so-called “ran-
dom” hexamer-nucleotide primers, or the inaccuracy of 
genome alignments, may become inflated or diminished 
using this approach. The total amounts of reads in each 
set are also the result of processing factors. In attempt 
to simplify, the statistical probability of observing read 
ratios normalized by the total read count is calculated 
by applying a Gaussian distribution to the entire read 
set, i.e. including all chromosomes. Recent work analys-
ing genetic crosses of P. falciparum laboratory strains 
employed a hidden Markov permutation of the Gauss-
ian distribution to improve CNV significance estimation 
[14]. While read coverage does not follow a normal dis-
tribution, at present, hidden Markov modelling requires 
library dependencies that are obtrusive to use, and so the 
software presently uses a less ideal distribution model.
Application to determine target of novel 
anti‑malarial compounds
Compound SJ733
The discovery of a novel anti-malarial agent was recently 
reported [2], and is now being tested for safety in humans. 
A key milestone for understanding the mechanism of 
action for SJ733 and its derivatives was to identify molec-
ular determinants of resistance. Resistant sub-clones of 
a susceptible parent strain were selected by long incu-
bations in concentrations of the compound that allowed 
very few organisms to live, and identified the resistance 
loci by comparing genome sequence data between parent 
and resistant sub-clones (mutants). Comparing genomic 
sequencing reads between parent and mutants revealed 
a few variants in most mutants, while only one gene con-
tained variants in all mutants: the gene encoding PfATP4, 
a sodium-dependent ATPase transporter [2].
The process of simultaneously assessing copy num-
ber and nonsynonymous variation in the search for the 
mutation that enables resistance to SJ733 is illustrated 
in Fig. 3. For a haploid genome under drug selection, the 
underlying genetic assumption is that the causal mutant 
allele will be driven to purity in the population of sur-
viving cells, and thus it is reasonable to set an absolute 
threshold of at least 90% for the proportion of reads that 
are variant at any given position. This threshold is a tun-
able parameter and would clearly need to be below 50% 
for a diploid genome, for example.
The sequencing data for this experiment are avail-
able through the NCBI Short Read Archive (SRA): 
SRX644366 is the mutant S83, SRX643297 is the par-
ent strain, and other resistant strains derived in par-
allel independent experiments can be found through 
SRP043648.
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The list of nonsynonymous variants found by Minori-
tyReport (Table  1) demonstrates the coincident emer-
gence of mutations in the same gene from 5 independent 
selection experiments. In fact, in 3 of 5 selections, the 
only mutation that passes these basic thresholds are 
those in PfATP4 [2]. Note that relaxing the mutant pro-
portion threshold would reveal several high scoring non-
synonymous variants, but essentially all of these belong 
to highly repeated gene families, such as the PfEMP1 
family of antigenic variation genes, which are inherently 
prone to spurious alignment. The appearance of these 
non-causal variants, such as transportin, in the data set 
exemplifies the rare occurrence of real or artifact passen-
ger mutations that may be reported, and also emphasizes 
the utility of analysing several independent selections.
Also, the CNV assessments differ between the granular 
genome-wide scan performed with 3000 nucleotide-long 
tiles (top) versus the chromosome-specific scan per-
formed with 300 nucleotide-long tiles (middle); while this 
was done to construct an illustrative figure with a rea-
sonable amount of data, it shows that tile size affects the 
appearance of copy number and likelihood calculations: 
larger tiles are recommended for more relevant probabil-
ity values. In the case of PfATP4, our analysis produced 
no evidence of copy number variation associated with 
resistance to the compound.
Apicoplast inhibitor MMV‑08138
The mechanism of action of a Plasmodium apicoplast 





















































Fig. 3 Nonsynonymous and copy number variant analyses to determine the drug target of anti-malarial drug SJ733. The relative copy number 
for 3000 nucleotide tiles across the entire P. falciparum genome are mapped across all chromosomes (top panel). The read support for susceptible 
parent (black) and resistant mutant (blue) strains show a relatively even distribution of sequencing reads. Zooming into a reanalysis of chromosome 
12 with 300 nucleotide tiles (middle panel) shows spurious copy number data in areas of relatively low read coverage. Zooming further in (bottom 
panel) shows that the variation that encodes P412T in ATPase4 (arrow) is present in 72 of 74 reads in the resistant mutant strain, but only 3 in 684 of 
the susceptible parent strain. This nonsynonymous mutation determines resistance to SJ733. Each panel is to scale
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SJ733, the genome sequence of sub-clones raised for 
resistance to the drug were compared against the sus-
ceptible parent strain. A single nonsynonymous variation 
(IspD L244I) not observed in the parent strain emerged, 
and reached nearly complete (98.9%) purity in the resist-
ant mutant shown in Fig.  4. With the default threshold 
settings, 23 putative variants are output for this sample 
by MinorityReport (Additional file 1: Table S1). As well, 
the causal mutant receives over twice the priority score of 
any other variant.
Dihydroorotate dehydrogenase inhibitor DSM1
We also previously demonstrated that P. falciparum can 
achieve drug resistance to the dihydroorotate dehydro-
genase inhibitor, DSM1, and perhaps generally, by ran-
domly amplifying a large AT-repeat flanked region of the 
genome, then specifically further amplifying the region 
in progeny that successfully evade the drug effects [1]. 
Amplified regions likely contain the drug target, which 
can also contain nonsynonymous mutations that further 
aid resistance. MinorityReport successfully identified the 
amplified region (Fig.  5), and 4 nonsynonymous muta-
tions (Additional file  2: Table S2) that were previously 
reported.
Conclusions
MinorityReport is a robust tool to rapidly identify the 
genetic differences between any two closely related 
organisms. It relates mapped sequence reads in SAM 
format from any alignment tool for both the mutant and 
parent genome, relative to a reference genome, and pro-
duces the set of variants that distinguishes the mutant 
from the parent. Output includes the spectrum of non-
synonymous changes, insertions or deletions, and copy 




















































Fig. 4 Nonsynonymous and copy number variant analyses to determine the drug target of apicoplast-specific inhibitor MMV-08138. Depictions 
match Fig. 3. These data show no significant copy number variation. The bottom panel shows that the variation that encodes L244I in IspD (arrow) 
is present in 358 of 362 overlapping reads from the resistant mutant strain, but absent in all 242 from the susceptible parent strain. This nonsynony-
mous mutation determines resistance to MMV-08138
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number variations in a presumed mutant relative to its 
parent. Tunable evidence filters prioritize reported vari-
ants based on relative proportions of read counts sup-
porting the genetic variant in the mutant versus parent 
data sets. Since MinorityReport is organism agnostic, it 
will be useful for both haploid and diploid genomes, as 
well as microorganisms and viruses.
The software is freely available, open source, and only 
requires Python with libraries included in standard distri-
butions (re, math, sys, and os). The R code for producing 
the data graphics shown in the Figures is also included in 
the github distribution (this has software library depend-
encies), and a “master” script that breaks the calculation 
into smaller parts by chromosome and launches them in 
parallel for faster calculation of nonsynonymous variants 
on machines with more processor cores than there are 
chromosomes in the genome.
Additional files
Additional file 1: Table S1. Nonsynonymous variant data for a Plasmo-
dium falciparum mutant strain raised for resistance to an apicoplast inhibi-
tor, versus the susceptible parent strain. The causal mutation, IspD L244I, 
reaches near purity in the mutant, is absent in the parent, and receives the 
highest priority score.
Additional file 2: Table S2. Nonsynonymous variant data for a Plasmo-
dium falciparum mutant strain raised for resistance to a dihydroorotate 
dehydrogenase inhibitor, versus the susceptible parent strain. Multiple 
mutations arise for all resistant strains, following the copy number varia-
tion and amplification shown in Fig. 5.
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SAM: Sequence Alignment/Map; GFF3: gene file format files; CNV: copy-num-
ber variant; SNP: single nucleotide polymorphism; PfATP4: sodium-dependent 
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dehydrogenase inhibitor.
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Fig. 5 Nonsynonymous and copy number variant analyses to determine the drug target of antimalarial compound DSM1. Depictions match Fig. 3. 
These data show a significant copy number variation from nucleotide 79,100 through 152,500 of chromosome 6, which determines resistance to 
DSM1
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